1646355-34-1: 7-(but-2-yn-1-yl)-8-(Dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione

7-(but-2-yn-1-yl)-8-(Dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione (CAS No: 1646355-34-1) Or 7-(but-2-yn-1-yl)-8-(Dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione,Linagliptin is a competitive, reversible inhibitor of DPP-4, which is an enzyme that degrades the incretin hormones glucagon-like peptide-1, is used to to decreased glycosylated hemoglobin and fasting plasma glucose.

Additional information on CAS 1646355-34-1

Catalogue No.

VE009616

CAS No.

1646355-34-1

Molecular Formula

C22H23N7O2

Molecular Weight

417.47 g/mol

Parent drug

Linagliptin

IUPAC Name

7-(but-2-yn-1-yl)-8-(Dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3, 7-dihydro-1H-purine-2, 6-dione

Synonyms

N/A

References

McGill, J. B. (2012). Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Therapeutic Advances in Endocrinology and Metabolism, 3(4), 113–124. https://doi.org/10.1177/2042018812449406

Status

In-stock